Join

Compare · SGEN vs TTNP

SGEN vs TTNP

Side-by-side comparison of Seagen Inc. (SGEN) and Titan Pharmaceuticals Inc. (TTNP): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both SGEN and TTNP operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • SGEN is the larger of the two at $23.34B, about 2319.0x TTNP ($10.1M).
  • SGEN has more recent analyst coverage (25 ratings vs 0 for TTNP).
MetricSGENTTNP
Company
Seagen Inc.
Titan Pharmaceuticals Inc.
Price
$228.86-0.01%
$6.29+53.04%
Market cap
$23.34B
$10.1M
1M return
-
+21.63%
1Y return
-
+1.27%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2001
News (4w)
0
0
Recent ratings
25
0
SGEN

Seagen Inc.

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

TTNP

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

Latest SGEN

Latest TTNP